Aisling Capital’s Cidara Therapeutics CDTX Stock Holding History

Aisling Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.78M	Sell	44,581 -6,476	-13%	-$218K	3.93%	3
2019 Q2	$1.72M	Hold	51,057	–	–	2.84%	4
2019 Q1	$2.71M	Hold	51,057	–	–	4.07%	4
2018 Q4	$2.4M	Hold	51,057	–	–	0.68%	5
2018 Q3	$4.49M	Hold	51,057	–	–	0.97%	6
2018 Q2	$5.31M	Hold	51,057	–	–	0.7%	6
2018 Q1	$4.08M	Hold	51,057	–	–	0.73%	6
2017 Q4	$6.94M	Hold	51,057	–	–	1.37%	7
2017 Q3	$8.27M	Hold	51,057	–	–	1.36%	8
2017 Q2	$7.66M	Hold	51,057	–	–	1.31%	9
2017 Q1	$7.96M	Hold	51,057	–	–	1.45%	12
2016 Q4	$10.6M	Hold	51,057	–	–	2.47%	10
2016 Q3	$11.7M	Hold	51,057	–	–	2.41%	13
2016 Q2	$10.5M	Buy	51,057 +84	+0.2%	+$20.3K	2.49%	14
2016 Q1	$12.9M	Hold	50,973	–	–	2.59%	14
2015 Q4	$17.5M	Hold	50,973	–	–	3.02%	13
2015 Q3	$13M	Buy	+50,973	New	+$14.6M	2.28%	16

Other funds holding CDTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Aisling Capital's CDTX Position: Q3 2019 in Review

Aisling Capital reduced its Cidara Therapeutics (CDTX) stake by 13% in Q3 2019, selling an estimated $218K and leaving 44,581 shares worth $1.78M. The position accounts for 3.93% of the portfolio, ranked #3.

Aisling Capital first reported a position in CDTX in Q3 2015 and has held it in 17 quarters since. The position peaked at $17.5M in Q4 2015. 39 funds tracked by Wall St. Rank hold CDTX as of Q3 2019.

Aisling Capital held 44,581 shares of Cidara Therapeutics worth $1.78M as of Q3 2019.
Aisling Capital sold 6,476 Cidara Therapeutics shares in Q3 2019, an estimated $218K.
Cidara Therapeutics made up 3.93% of Aisling Capital's portfolio in Q3 2019, its #3 holding.
Aisling Capital first reported a position in Cidara Therapeutics in Q3 2015 and has held it in 17 quarters since.
Aisling Capital's Cidara Therapeutics position peaked at $17.5M in Q4 2015.
39 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2019.

Based on Aisling Capital's 13F filing for Q3 2019, filed 13 Nov 2019.